Somatostatin: Brands, Price & Uses in Bangladesh

Somatostatin is a synthetic cyclic peptide identical to the naturally occurring hormone somatostatin-14. It is administered as a continuous intravenous infusion under hospital supervision for the following indications, classified by strength of evidence:

Established, guideline-supported uses

• Bleeding oesophageal and gastric varices - Somatostatin is used, together with endoscopic therapy, to control acute variceal bleeding in patients with portal hypertension (e.g., cirrhosis). This use is supported by international consensus guidelines on portal hypertension, and Somatostatin/its analogues are included in resource protocols for variceal haemorrhage.
• Severe upper gastrointestinal bleeding (e.g., bleeding peptic ulcer) - used as an adjunct to endoscopic haemostasis to reduce gastric acid and splanchnic blood flow while definitive treatment is arranged.

Adjunctive / supportive uses

• Pancreatic and enterocutaneous (intestinal) fistulas - Somatostatin reduces pancreatic exocrine and intestinal secretions, which can decrease fistula output and support closure, usually alongside nutritional support and surgical management.
• Prevention of complications after pancreatic surgery - used peri-operatively in some centres to reduce pancreatic secretion and the risk of post-operative pancreatic fistula.

Off-label / less-established uses

• Adjunct in acute pancreatitis to reduce pancreatic secretion, although evidence for a clear outcome benefit is limited and this is not a standard first-line indication.

Somatostatin is always used under close medical/hospital supervision as a continuous intravenous infusion; it is not intended for outpatient or self-administered use.

Somatostatin is given only by continuous intravenous infusion, in hospital, with cardiac and glucose monitoring. Typical adult dosing by indication is summarised below; the treating physician individualises the exact regimen.

Renal/hepatic impairment

There is no well-established, standardised dose-adjustment schedule for renal or hepatic impairment; Somatostatin should be used with caution and closer monitoring in these patients, as clearance may be reduced (see Precautions and Warnings).

Interrupted infusion

Because Somatostatin is given as a continuous hospital infusion, dosing is managed entirely by the treating medical team; there is no patient-administered "missed dose" scenario.

Somatostatin is generally used for short periods under hospital monitoring; reported adverse effects include:

Common

• Nausea, vomiting, abdominal cramping or bloating
• Flushing of the face
• Dizziness or headache
• Hyperglycaemia or hypoglycaemia (see Precautions and Warnings)
• Injection/infusion site reactions

Less common/serious

• Bradycardia and other cardiac rhythm disturbances
• Gallstone formation or biliary sludge with prolonged use
• Rare hypersensitivity reactions

Patients should be monitored for these effects throughout the infusion, and any severe or persistent symptoms should be reported to the treating physician immediately.